Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | BPTF | Q12830 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | BCHE | P06276 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.52 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.52 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipidacrine SCHEMBL29382648 | 1.00 | ACHE (1.00) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL7536973 | 0.97 | ACHE (0.95) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL1032513 | 0.97 | ACHE (0.95) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL20681035 | 0.97 | ACHE (0.95) | ACHEMAPK1MEN1KMT2ABPTF | |
| Octaaminoacridine SCHEMBL12507982 | 0.97 | ACHE (1.00) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL6633743 | 0.95 | ACHE (0.91) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL29751898 | 0.95 | ACHE (0.91) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL22021195 | 0.92 | ACHE (0.86) | ACHEMAPK1MEN1KMT2ABPTF | |
| SCHEMBL30162181 | 0.92 | ACHE (0.86) | ACHEMAPK1MEN1KMT2ABPTF | |
| Ipidacrine SCHEMBL7540743 | 0.87 | ACHE (0.76) | ACHEMAPK1MEN1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635489-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | Dr.Noah Biotech Inc. (KR) | 2025-10-22 | — | — | EP | claimed |
| US-20240423965-A1 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | QAAM PHARMACEUTICALS LLC (US) | 2024-12-26 | — | — | US | claimed |
| EP-4473964-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Dr.Noah Biotech Inc. (KR) | 2024-12-11 | — | — | EP | claimed |
| CN-118647376-A | Compositions comprising a beta blocker and a cholinesterase inhibitor for the treatment of neurodegenerative diseases | 诺亚博士生物科技有限公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2024128473-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | 닥터노아바이오텍 주식회사 | 2024-06-20 | — | — | WO | claimed |
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | DR.NOAH BIOTECH INC. (KR) | 2024-05-09 | — | — | US | claimed |
| US-20240066017-A1 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | DR. NOAH BIOTECH INC. (KR) | 2024-02-29 | — | — | US | claimed |
| EP-4284337-A1 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | QAAM Pharmaceuticals, LLC (US) | 2023-12-06 | — | — | EP | claimed |
| EP-4285901-A1 | COMPOSITE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BRAIN DISEASE, COMPRISING CHOLINESTERASE INHIBITOR AND ANTIOXIDANT | Dr.Noah Biotech Inc. (KR) | 2023-12-06 | — | — | EP | claimed |
| WO-2023149682-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | 닥터노아바이오텍 주식회사 | 2023-08-10 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| JP-2000511873-A | — | — | 2000-09-12 | — | — | JP | claimed |
| WO-2000025821-A1 | METHOD OF TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME AND CORRESPONDING MEANS | HEDNER JAN (SE) | 2000-05-11 | — | — | WO | claimed |
| US-6034117-A | Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method | PHARMAPNEA AB (SE) | 2000-03-07 | — | — | US | claimed |
| WO-1999047131-A2 | COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-23 | — | — | WO | claimed |
| EP-0923370-A2 | METHOD OF TREATING AND DIAGNOSING SLEEP DISORDERED BREATHING AND MEANS FOR CARRYING OUT THE METHOD | A+ Science Invest AB (SE) | 1999-06-23 | — | — | EP | claimed |
| US-5869088-A | PREPARATION CONTAINING FATTY ACID, FATTY ACID ESTER OR ALCOHOL AS ABSORPTION ENHANCER | NIKKEN CHEMICALS CO., LTD (JP) | 1999-02-09 | — | — | US | claimed |
| EP-0793963-A1 | PERCUTANEOUSLY ADMINISTRABLE PREPARATION | Nikken Chemicals Company, Limited (JP) | 1997-09-10 | — | — | EP | claimed |
| WO-1997022339-A1 | METHOD OF TREATING AND DIAGNOSING SLEEP DISORDERED BREATHING AND MEANS FOR CARRYING OUT THE METHOD | HEDNER JAN (SE) | 1997-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ACHE, BACE1, CHRNB4 | ACHE 1/4885MAPK1 1799/4885MEN1 4422/4885 |
| US-20240066017-A1 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHAT | ACHE 1/4885MAPK1 4071/4885MEN1 2341/4885 |
| US-20240423965-A1 | FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS | ACHE, BCHE, CHRM1 | ACHE 1/4885MAPK1 3576/4885MEN1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.